Drug-drug interaction with oral antivirals for the early treatment of COVID-19
| Errataetall: |
CommentOn: Int J Infect Dis. 2022 Sep;122:599-601. - PMID 35803465 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:127 |
|---|---|
| Enthalten in: |
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases - 127(2023) vom: 15. Feb., Seite 171-172 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Vuorio, Alpo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 30.01.2023 Date Revised 24.02.2023 published: Print-Electronic CommentOn: Int J Infect Dis. 2022 Sep;122:599-601. - PMID 35803465 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijid.2022.11.039 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM349829802 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM349829802 | ||
| 003 | DE-627 | ||
| 005 | 20231226043551.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijid.2022.11.039 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1166.xml |
| 035 | |a (DE-627)NLM349829802 | ||
| 035 | |a (NLM)36470504 | ||
| 035 | |a (PII)S1201-9712(22)00632-4 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Vuorio, Alpo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug-drug interaction with oral antivirals for the early treatment of COVID-19 |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.01.2023 | ||
| 500 | |a Date Revised 24.02.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: Int J Infect Dis. 2022 Sep;122:599-601. - PMID 35803465 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 4 | |a Atherosclerotic cardiovascular disease | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Nirmatrelvir/ritonavir | |
| 650 | 4 | |a Statins | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 700 | 1 | |a Raal, Frederick |e verfasserin |4 aut | |
| 700 | 1 | |a Kovanen, Petri T |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases |d 1998 |g 127(2023) vom: 15. Feb., Seite 171-172 |w (DE-627)NLM094730857 |x 1878-3511 |7 nnns |
| 773 | 1 | 8 | |g volume:127 |g year:2023 |g day:15 |g month:02 |g pages:171-172 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijid.2022.11.039 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 127 |j 2023 |b 15 |c 02 |h 171-172 | ||